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Introduction
IL-1β is a proinflammataory cytokine that has myriad
effects on cells, increasing proliferation, activating inflam-
matory responses, and inducing matrix remodeling
through the production of neutral proteases. Since most
cells can both express and respond to IL-1β, complex
signaling programs are likely required to modulate the
timing and magnitude of responses to this cytokine [1]. It
is well documented that elevated expression of IL-1β in
the joint results in the activation of inflammatory and
degradative programs in synovial cells, contributing to the
progression of rheumatoid arthritis [2]. Recent work by
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Recent work has established that IL-1β plays a central role in the inflammation and connective tissue
destruction observed in both rheumatoid arthritis and osteoarthritis. These processes result from the
ability of this inflammatory cytokine to activate expression of genes for neutral proteases, such as the
matrix metalloproteinases. While IL-1β activates matrix metalloproteinase genes within several hours, it
also activates immediate early genes, which are required for the later expression of matrix
metalloproteinases and other arthritis-perpetuating genes, are also activated. To identify putative
immediate early genes involved in IL-1β-mediated arthritic disease, a chondrocytic cell line (SW1353)
was stimulated with this cytokine for 2 hours, total RNA was isolated, and expressed genes were
identified by microarray analysis. This analysis identified alterations in the expression of multiple
transcription factors, cytokines, growth factors and their receptors, adhesion molecules, proteases,
and signaling intermediates that may contribute to inflammation and cartilage destruction in arthritis.
Interestingly, confirmation of the expression of activating protein-1 family members by reverse
transcriptase polymerase chain reaction revealed a preferential increase in junB, a known
transcriptional antagonist of c-jun. The failure to observe induction of early growth response gene-1,
which was detected by reverse transcriptase polymerase chain reaction to be substantially and
transiently induced by 1 hour of IL-1 treatment, may be explained by the known instability of the
message after early induction. However, this analysis has identified numerous IL-1β-responsive genes
that warrant further investigation as mediators of disease in arthritis.
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Hasty and coworkers [3] has demonstrated that local
expression of IL-1β by articular chondrocytes activates
autocrine gene expression, which contributes to the
pathogenesis of osteoarthritis (OA). Furthermore, IL-1-
receptor antagonists are effective inhibitors of inflamma-
tion and connective tissue destruction in animal models of
arthritis [2,4,5]. Together, these studies implicate IL-1β as
a central mediator of pathogenesis in arthritis.
Activation of this pathologic process is complex, most
likely involving the activation or repression of numerous
signal/transduction pathways, with subsequent effects on
many genes. Our previous work has focused on the path-
ways by which IL-1β induces several members of the
family of matrix metalloproteinases (MMPs), enzymes that
are active at neutral pH and that collectively degrade the
various components of the extracellular matrix. Specifi-
cally, we have focused on MMP-1 and MMP-13, interstitial
collagenases that have the unique ability to initiate cleav-
age of the triple helix comprising the stromal collagens
types I, II, and III. Elevated expression of MMP-1 and
MMP-13 by stromal cells and chondrocytes in response to
IL-1β contributes to the pathogenesis of connective tissue
disorders [6–11]. Studies from this laboratory and others
showed that IL-1 activates MMP-1 and MMP-13 gene
expression through common signaling pathways [11–15].
Specifically, nuclear translocation of NF-κB and mitogen-
activated protein kinase (MAPK) stimulation of activator
protein-1 (AP-1) are required for transcription of cytokine-
induced MMP-1 and MMP-13. Furthermore, cycloheximide
blocks mRNA expression of both collagenases [11,16],
indicating that expression of immediate early genes is
required for MMP-1 and MMP-13 gene expression. Thus,
IL-1β activation of collagenase gene expression requires
the increased expression of a panel of essential transcrip-
tion factors and signaling intermediates, as well as the ini-
tiation of signaling cascades that activate these factors.
IL-1 also contributes to the pathogenesis of arthritis by
increasing the proliferation of mesenchymal cells and by
enhancing the expression of other inflammatory mediators
[17–19]. This complex alteration in cellular phenotype
probably involves the coordinated increase and decrease
of genes for cytokines and growth factors, adhesion mole-
cules, and signaling intermediates. The recent availability
of microarray technology has made it possible to perform
an extensive analysis of IL-1 modulation of genes in cells
that are central players in arthritic disease.
We therefore carried out a microarray analysis of IL-1β-
stimulated chondrocytic cells in order to identify immedi-
ate early genes that could contribute to phenotypic
changes relevant to OA. In these studies, we used the
human chondrosarcoma cell line SW1353, for three
important reasons. First, we, and others, have found that
when treated with IL-1β, SW1353 cells serve as an
appropriate model for primary chondrocytes in OA
[11,20–22]. Second, the amount of total RNA required for
microarray analysis precludes the use of primary human
chondrocytes for these studies. Third, the inherent genetic
variation in primary human chondrocyte cultures could
bias the gene expression profile and lead to erroneous
conclusions. We found increased expression of a large
cohort of transcription factors, cytokines, growth factors,
and signaling intermediate genes that are potential regula-
tors of metalloproteinase gene expression, proliferation,
and sustained inflammation. Alternatively, this was accom-
panied by a decrease in a modest number of genes also
belonging to these categories, suggesting that IL-1β sub-
stantially reprograms gene expression in chondrocytes. A
subset of these IL-1β-stimulated genes was then con-
firmed by semiquantitative reverse transcriptase poly-
merase chain reaction (RT-PCR). This characterization of
IL-1β-induced immediate early genes in chondrocytic cells
identifies candidate mediators of the expression of colla-
genase genes in arthritis.
Materials and methods
Cell culture
SW1353 chondrosarcoma cells were grown to conflu-
ence in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum (Hyclone, Logan, UT,
USA), penicillin/streptomycin, and L-glutamine (Cellgro,
Mediatech, Herndon, VA, USA). At the beginning of each
experiment, cells were washed three times with Hank’s
buffered sterile saline (Cellgro) to remove traces of serum
and were placed in Dulbecco’s modified Eagle’s medium
containing 0.2% lactalbumin hydrolysate (Gibco/BRL,
Rockville, MD, USA). Then cells were either left unstimu-
lated or treated with 10 ng/ml recombinant IL-1β
(Promega, Madison, WI, USA). This concentration of IL-1
was found to be optimal for activation of MMP-13 gene
expression in these cells (data not shown).
Harvest and microarray analysis of mRNA
For microarray analysis, two confluent 150-mm plates of
SW1353 cells were cultured in lactalbumin hydrolysate,
or lactalbumin hydrolysate plus 10 ng/ml IL-1β, for
2 hours. Cells were then washed with Hank’s buffered
sterile saline solution and homogenized in 2 ml Triazol
Reagent (Gibco/BRL), and RNA was purified in accor-
dance with the manufacturer’s instructions. The RNA
pellets were stored in 70% ethanol and shipped on dry ice
to Clontech Laboratories (Palo Alto, CA, USA) via express
courier. Clontech analyzed the RNA using their Atlas
Human Cancer 1.2K array (1176 unique genes) and
AtlasImage 1.0 software. We chose this data baseline
because it represents a large number of genes that may
be expressed during development and again during
disease pathology. We further classified genes that
increased or decreased by twofold or more, and sorted
them using Microsoft Excel.Reverse transcriptase polymerase chain reaction
A subset of genes whose expression was increased by
IL-1β was then confirmed using a radioactive RT-PCR
assay. Briefly, RNA was treated with DNAse I and then
2 µg was reverse transcribed with Moloney murine
leukemia virus reverse transcriptase and oligodT primers.
One tenth of the reverse transcriptase reaction was ampli-
fied using gene-specific primers, Platinum Taq DNA poly-
merase and 33PdATP. Single-band products were
resolved on native acrylamide gels and visualized by
autoradiography. Table 1 shows the gene-specific primers
that were used.
Results and discussion
Table 2 shows the results of an analysis using Clontech’s
Human Cancer 1.2K Array and total RNA from SW1353
cells treated with IL-1β (10 ng/ml) for 2 hours. This analysis
revealed substantial increases or decreases in the expres-
sion of several known IL-1β-responsive genes. These
include transcription factors (panel A), cytokines, growth
factors, and their receptors (panel B), proteases, matrix
proteins, and adhesion molecules (panel C), as well as sig-
naling intermediates and tumor suppressors (panel D).
We focused on genes for transcription factors because
they have been reported as IL-1-responsive immediate
early genes in chondrocytes [23]. Members of the NF-κB,
AP-1, and ets families of transcription factors substantially
increased in the Human Cancer 1.2K array (see Table 2,
panel A). To confirm the effect of IL-1β on AP-1 family
members, we assayed Jun family members by RT-PCR
(Fig. 1). We found that the c-Jun and JunB genes
increased transiently within 1 hour of IL-1 treatment,
before the induction of the MMP-13 gene. The expression
profiles for c-Jun and JunB were similar to the profile for
egr-1, another immediate early gene in IL-1-stimulated
chondrocytes [23]. In contrast, the JunD gene was consti-
tutively expressed, and IL-1β increased this expression
modestly. These data show that in IL-1β-stimulated chon-
drocytes, all three Jun family members are expressed and
can contribute to MMP gene expression. Furthermore, RT-
PCR analysis of the JunB gene (Fig. 1) validated the gene
expression profile derived from the Human Cancer 1.2K
array (Table 2, panel A).
Transcription factor genes that were modulated by IL-1β
included members from the NF-κB family (relB, p100/p52,
p105/p50, IκB-ε, c-rel, and p65), the AP-1 family (fra-1
and junB), and the ETS family (ets-1). While it is well
established that NF-κB proteins translocate to the nucleus
upon IL-1 stimulation [24], we were surprised to find so
many family members expressed simultaneously. This sug-
gests that in IL-1-stimulated chondrocytes, NF-κB family
members may compete for dimerization partners and for
binding sites in responsive genes.
Members of the AP-1 family of transcription factors are
essential transcriptional activators for both the MMP-1 and
MMP-13 genes [25–27], and these transcription factors
are activated by extracellular stimuli through MAPK path-
ways [28]. JunB was identified as an IL-1-inducible gene
in chondrocytes by the Human Cancer 1.2K array
(Table 1) and this finding was confirmed by RT-PCR
(Fig. 1). Levels of JunB mRNA peaked within 1 hour of IL-1
stimulation and began to decline after 2 hours. This was
somewhat surprising, since MAPK pathways do not acti-
vate JunB [29] and in some systems JunB antagonizes
transcriptional activation by c-Jun [30]. Since c-Jun, JunB,
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Table 1
PCR primers and conditions
Annealing Product 
Gene Primers temperature Cycles length*
MMP-13 CCAGTGGTGGTGATGAAGATG Sense 52°C 25 143
TTCTCGGAGCCTCTCAGTC Antisense
c-Jun GGAAACGACCTTCTATGACGATGCCCTCAA Sense 63°C 22 316
GAACCCCTCCTGCTCATCTGTCACGTTCTT Antisense
JunD GAGTGTTCGATTCTGCCCTA Sense 53°C 22 214
TGTGGACTCGTAGCAAAACA Antisense
JunB CCAGTCCTTCCACCTCGACGTTTACAAG Sense 58°C 22 257
GACTAAGTGCGTGTTTCTTTTCCACAGTAC Antisense
egr-1 TCCCGGCTCCTCGACCTAC Sense 60°C 25 177
AAGGTTGCTGTCATGTCCGAAAG Antisense
GAPDH was amplified using Clontech’s human GPDH amplimer set with an annealing temperature of 58°C and 25 cycles of amplification. 
MMP-13 = matrix metalloproteinase-13; egr-1 = early growth response gene-1. *Measured in base pairs.Arthritis Research    Vol 3 No 6 Vincenti and Brinckerhoff
Table 2
IL-1-responsive genes in chondrocytic cells
Fold Fold
↑↓Gene description Genbank#
Panel A: Transcription Factors/RNA-binding Proteins
18.0 I-rel (RELB) M83221
17.0 nuclear factor NF-kappa-B p100 subunit; nuclear factor NF-kappa-B p52 subunit; H2TF1; oncogene lyt-10 X61498
15.7 interferon regulatory factor 1 (IRF1) X14454
13.7 major histocompatibility complex enhancer-binding protein MAD3 M69043
8.1 nuclear factor kappa-B DNA binding subunit (NF-kappaB; NFKB) M58603
5.5 octamer-binding transcription factor 2 (oct-2; OTF2); lymphoid-restricted immunoglobulin octamer  M36542
binding protein NF-A2; POU2F2
4.7 IkappaB epsilon (IKBE) U91616
3.0 c-rel proto-oncogene protein X75042
2.8 fos-related antigen (FRA1) X16707
2.4 STAT-induced STAT inhibitor 3 AB004904
2.4 erythroblastosis virus oncogene homolog 1 (ETS-1); p54 J04101
2.3 jun-B M29039
2.2 ELAV-like neuronal protein 1 (HEL-N1) + HEL-N2 U12431 + 
U29943
2.0 myb proto-oncogene; c-myb M15024
2.0 NF-kappaB transcription factor p65 subunit; RELA; NFKB3 L19067
2.0 transcription factor erf-1; AP2 gamma transcription factor U85658
2.0 early growth response alpha (EGR alpha) S81439
6.0 homeobox protein HOX-D3; HOX-4A D11117
2.0 retinoblastoma-like protein 2 (RBL2; RB2); 130-kDa retinoblastoma-associated protein X74594
2.0 mothers against dpp homolog 4 (SMAD4); MADR4; pancreatic carcinoma gene 4 (DPC4) U44378
Panel B: Cytokines/Growth Factors/Receptors
21 leukemia inhibitory factor precursor (LIF); differentiation-stimulating factor (D factor); melanoma-derived  X13967; 
LPL inhibitor (MLPLI); HILDA M63420
8.7 interleukin-11 (IL-11); adipogenesis inhibitory factor (AGIF) M57765
6.1 interferon-gamma (IFN-gamma) receptor beta subunit precursor; IFN-gamma accessory factor 1 (AF1);  U05875
IFN-gamma transducer 1 (IFNGT1)
6.1 interleukin-6 precursor (IL-6); B-cell stimulatory factor 2 (BSF2); interferon beta-2 (IFNB2);  X04602; 
hybridoma growth factor M14584
5.9 heparin-binding EGF-like growth factor (HBEGF); diphtheria toxin receptor (DTR) M60278
5.0 interferon gamma-induced protein precursor (gamma-IP10) X02530
4.3 putative serine/threonine protein kinase PRK U56998
4.3 CD40 receptor-associated factor 1 (CRAF1) U21092
3.6 platelet-derived growth factor A subunit precursor (PDGFA; PDGF1) X06374
3.0 bone morphogenetic protein 3B precursor (BMP3B); growth differentiation factor 10 (GDF10);  D49493
bone inducing protein (BIP)
2.5 CD40 ligand (CD40-L); tumor necrosis factor (TNF)-related activation protein (TRAP); T-cell antigen GP39 L07414
2.1 interleukin-12 beta subunit precursor (IL-12B); cytotoxic lymphocyte maturation factor 40-kDa subunit M65290
(CLMF p40); NK cell stimulatory factor subunit 2 (NKSF2)
2.1 glial growth factor 2 precursor (GGFHPP2); neuregulin; heregulin-beta3 + neu differentiation factor +  L12260; 
heregulin-alpha L12261 + 
U02326 + 
M94165
2.0 platelet-derived growth factor B subunit precursor (PDGFB; PDGF2); bacaplermin; c-sis X02811; 
X02744; 
M12783; 
M16288
7.8 bone morphogenetic protein 4 (BMP4) + bone morphogenetic protein 2B (BMP2B) D30751 + 
M22490
2.3 platelet-derived growth factor receptor alpha subunit (PDGFRA); CD140A antigen M21574
2.3 platelet-derived growth factor receptor beta subunit (PDGFRB); CD140B antigen M21616
Continued overleafAvailable online http://arthritis-research.com/content/3/6/381
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Table 2
Continued
Fold Fold
↑↓Gene description Genbank#
Panel C: Proteases/Matrix Proteins
3.0 matrix metalloproteinase 13 (MMP-13); collagenase 3 precursor X75308
2.3 matrix metalloproteinase 7 (MMP-7); matrilysin X07819
2.1 matrix metalloproteinase 12 (MMP-12); metalloelastase L23808
2.1 collagen 6 alpha 2 subunit (COL6A2) M34570
2.1 tissue-type plasminogen activator precursor (T-plasminogen activator; TPA) M15518; 
X07393; 
M18182
2.0 urokinase-type plasminogen activator receptor GPI-anchored form precursor (U-PAR); monocyte activation  U08839; 
antigen MO3; CD87 antigen M83246; 
X51675
3.0 chymotrypsin-like protease CTRL-1 precursor X71874
2.0 cysteine protease D55696
Adhesion Molecules
3.5 ninjurin-1 U72661
3.0 desmocollin 3A/3B precursor (DSC3) + desmocollin 4 (DSC4) X83929 + 
D17427
2.8 tenascin precursor (TN); hexabrachion (HXB); cytotactin; neuronectin; GMEM; miotendinous antigen;  X78565; 
glioma-associated extracellular matrix antigen M55618
2.2 alpha-catenin related protein (CAPR); alpha 2 catenin (CTNNA2); alpha N-catenin M94151
4.0 opioid-binding protein/cell adhesion molecule precursor (OBCAM); opioid-binding cell adhesion  L34774
molecule (OPCML)
3.0 integrin beta 4 (ITGB4); CD104 antigen X53587; 
X52186; 
X51841
2.2 integrin alpha 1 (ITGA1); laminin & collagen receptor; VLA1; CD49A antigen X68742
Panel D:  Signaling Intermediates
7.0 rho6 protein Y07923
2.9 Gem; induced immediate early protein; ras family member (ras-like protein KIR) U10550
2.6 regulator of G protein signaling 3 (RGS3; RGP3) U27655
2.5 dual-specificity protein phosphatase 8; HVH5 U27193
2.3 death receptor 5 (DR5); cytotoxic TRAIL receptor 2 (TRICK2A) AF016268
2.1 protein kinase DYRK3 Y12735
2.1 jagged 1 (HJ1) AF028593
6.0 C-fgr proto-oncogene (p55-FGR); SRC2 M19722
4.0 rho7 protein X95456
3.0 GTP-binding protein ras associated with diabetes (RAD1) L24564
2.7 rho-associated coiled-coil containing protein kinase p160ROCK U43195
2.5 frizzled L37882
2.3 cyclin-dependent kinase 4 inhibitor D (CDKN2D); p19-INK4D U40343; 
U20498
2.3 phosphotyrosyl phosphatase activator X73478
2.3 protein kinase C-binding protein RACK7 U48251
2.2 A-raf proto-oncogene serine/threonine-protein kinase; PKS2 L24038
2.2 STE20-like kinase; MST2 U26424
2.1 phosphorylase B kinase beta regulatory subunit X84908
2.0 protein phosphatase 2A B56-alpha L42373
Tumor Suppressors
11.0 melanoma differentiation-associated protein 7 precursor (MDA7) U16261
2.3 tumor suppressor protein DCC precursor; colorectal cancer suppressor X76132and JunD are all expressed in IL-1-treated SW1353 chon-
drocytic cells, it is not clear which family member is
responsible for transcriptional activation of collagenase
genes. Perhaps the functional transcriptional complex is
determined by induced expression and activation of AP-1
accessory proteins, such as the Fos family member Fra-1,
or the ets family member ets-1 [31]. This cohort of AP-1,
Fos, and ets family members may also preferentially bind
to different AP-1 sites in MMP promoters, with subtle
effects on gene expression [32].
egr-1 is an IL-1-inducible immediate early gene in chon-
drocytes [23] and has been implicated in the elevated
MMP-1 gene expression observed in rheumatoid synovio-
cytes [33,34]. Surprisingly, egr-1 expression was
increased only 1.3-fold in this Human Cancer 1.2K array
(data not shown). However, when this gene was analyzed
by RT-PCR, we found a robust increase in egr-1 mRNA
within 1 hour of IL-1 stimulation, which declined signifi-
cantly by 2 hours (Fig. 1). Thus, the relatively short half-life
of egr-1 mRNA resulted in an underestimation of IL-1
induction of this gene in the microarray. It is therefore
probable that an array using RNA from cells treated for 1
hour with IL-1 would identify additional important genes.
IL-1β repressed three transcription factor genes, including
HOX-4A, the retinoblastoma-like protein 2, and mothers
against dpp homologue 4 (SMAD4). SMAD4 contributes
to transforming growth factor-β (TGF-β)-dependent tran-
scription of the alpha 2(I)-collagen (COL1A2) [35] and
aggrecan [36] genes. Furthermore, our microarray data
demonstrated that IL-1 inhibited Col2A1 expression by
1.6-fold in SW1353 cells (data not shown). It has been
reported that IL-1 inhibition of Col2A1 gene expression
requires the p38 MAPK pathway [37]. Perhaps inhibition
of SMAD4 synthesis is another component of IL-1-depen-
dent Col2A1 gene repression. While IL-1 promotes carti-
lage degradation through MMP synthesis and inhibits
matrix deposition by reducing Col2A1 gene expression,
TGF-β has the opposite effect on chondrocytes [3]. Thus,
it is tempting to speculate that IL-1 antagonizes the effects
of TGF-β by blocking expression of essential signaling
intermediates, such as SMAD4.
Cytokines and growth factors and their receptors were a
major group of IL-1-modulated genes in chondrocytes
(Table 2, panel B). For instance, leukemia inhibitor factor
precursor (LIF) was substantially induced by IL-1β in
SW1353 cells, and this is consistent with previous
reports of LIF as an IL-1-responsive gene in chondrocytes
[38,39]. Recently, LIF was reported to induce MMP-13
gene expression [40], and this may contribute to the role
of this cytokine in arthritis pathology [38]. IL-6 expression
was increased in IL-1-treated cells, and while this may
affect a variety of cellular functions in chondrocytes, this
cytokine does not seem to be required for IL-1-induced
suppression of proteoglycan synthesis in cartilage [41].
Interestingly, there was a concurrent increase in expres-
sion of platelet-derived growth factor (PDGF) subunits,
and a decrease in PDGF receptor subunits. Perhaps this
is a mechanism of ensuring paracrine, but not autocrine,
effects of PDGF in cytokine-stimulated chondrocytes. The
role of growth factors in IL-1-dependent effects is not
clear cut, since IL-1 can both induce and inhibit prolifera-
tion of chondrocytes [17]. However, in the present model
of SW1353 cells under serum-free conditions, we did not
observe a mitogenic effect of IL-1 (data not shown).
Bone morphogenetic protein 4 (BMP4) is a member of the
TGF-β superfamily of proteins and is required for chondro-
cyte differentiation and cartilage maintenance [42,43]. The
observed suppression of its expression in chondrocytes by
IL-1β (Table 2, panel B) is consistent with a previous report
in osteoblastic cells [44] and suggests that IL-1β may
enhance cartilage degradation by blocking an essential
autocrine signal for chondrocyte maturation and function.
IL-1 induction of several MMP family members is seen,
including collagenase-3 (MMP-13), matrilysin (MMP-7),
and metalloelastase (MMP-12) (Table 2, panel C). The col-
lagenase-1 (MMP-1) gene was not significantly induced in
Arthritis Research    Vol 3 No 6 Vincenti and Brinckerhoff
Figure 1
Early gene expression in IL-1-treated SW1353 chondrocytes.
SW1353 cells were stimulated for the indicated times with IL-1β (10
ng/ml) and total RNA was isolated. RNA was treated with DNAse I and
then reverse transcribed with Moloney murine leukemia virus reverse
transcriptase and oligodT primers. A tenth of the reverse transcriptase
reaction was amplified using gene-specific primers, Platinum Taq DNA
polymerase, and 33PdATP. Single-band products were resolved on
native acrylamide gels and visualized by autoradiography.this array, and this is consistent with our previous findings
that MMP-1 is expressed at lower levels than MMP-13 in
SW1353 cells [11]. Furthermore, the magnitude of
increase observed for these MMP genes was modest,
despite the fact that MMP genes are strongly induced in
response to IL-1β. However, the most likely explanation for
the low level of induction seen here is the fact that MMPs
are not ‘early response genes’. Rather, they are the down-
stream targets of the signal/transduction pathways and
transcription factors that do represent early responses.
Indeed, RT-PCR confirmed that MMP-13 mRNA continues
to increase 4 hours after IL-1 treatment (Fig. 1). This is
consistent with our previously published finding that
steady-state MMP-13 mRNA levels peak 12 hours after
IL-1 treatment of chondrocytes [11].
Tenascin, an adhesion molecule that is expressed during
cartilage development [45], was induced by IL-1β in
SW1353 cells (Table 2, panel C). Interestingly, the
tenascin gene has been reported to be IL-1-inducible in
synovial cells and chondrocytes, and its expression is
enhanced in rheumatoid arthritis and OA [46,47]. A possi-
ble physiologic consequence of IL-1β-induced tenascin
expression is that it may promote chondrocyte migration
towards the sites of lesions in OA [47]. IL-1β coordinately
reduced expression of integrin α1, a cell-adhesion mole-
cule that chondrocytes use to bind to type II collagen [48].
Thus, IL-1β treatment may modify adhesion molecule
expression, so that matrix adhesion is compromised.
We found that IL-1β changed the expression levels for
several signaling proteins and tumor suppressor genes
(Table 2, panel D), but the significance of these changes is
not clear. Proteins associated with G-protein signaling were
both increased (rho6, Gem, and regulator of G protein sig-
naling) and decreased (rho7, RAD1, and p160ROCK).
Jagged, which is a transmembrane ligand for the Notch sig-
naling pathway [49], is induced by IL-1β. Interestingly,
jagged-1 is important for epithelial–mesenchymal cell inter-
action in development [50], and mutations in the jagged
gene lead to Alagille syndrome, a congenital connective
tissue disorder whose hallmarks include craniofacial and
vertebral deformities [51]. Zhao and colleagues [52] identi-
fied frizzled (denoted FZD2) as the human homologue of
the  Drosophila polarity-determining gene. Of potential
importance is the fact that frizzled family members have
recently been implicated by Carson and colleagues in
rheumatoid arthritis [53]. A new frizzled family member that
is expressed in chondrocytes and is involved in skeletal mor-
phogenesis has been described [54]. Perhaps down-regu-
lation of frizzled family members by IL-1β is deleterious to
chondrocyte function and can contribute to OA.
Conclusions
Along with confirming changes in gene expression already
known to be associated with IL-1β stimulation, chondro-
cyte biology, and MMP gene regulation, this microarray
identified several other induced and repressed genes
whose roles in chondrocyte biology are yet to be defined.
While the significance of these findings in terms of under-
standing IL-1 effects on chondrocytes is still uncertain, the
documentation of these changes in gene expression may
provide the basis for future studies on the molecular effects
of IL-1 on chondrocytes and on other cell types as well.
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